Epigenomic pathways in cancer and in cancer immunotherapy
- đ¤ Speaker: Shelley Berger, Epigenetics Institute, Departments of Cell and Developmental Biology, Genetics, Biology, University of Pennsylvania
- đ Date & Time: Thursday 23 February 2017, 16:00 - 17:00
- đ Venue: CRUK CI Lecture Theatre
Abstract
Cancer is both a genomic and epigenomic disease, given that numerous chromatin pathways have been implicated as drivers in cancer. Our study of p53 in human cancer has revealed an important role of epigenomic regulation in several cancers involving gain-of-function mutant p53, and in teratocarcinoma cancer, which involves wild type p53. In the former case, mutant p53 drives expression of gene-activating histone modifiers, and in the latter case, wild type p53 is modified by gene-repressive modifications â in both cases permitting the expression of growth accelerating genes and pathways. Immunotherapy is a new and exciting area of clinical cancer treatment. While some individuals respond, others show resistance. We are investigating epigenetic pathways that may inhibit effective cancer immunotherapy, and other epigenetic pathways that may provide exceptionally potent response.
Series This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.
Included in Lists
- All Talks (aka the CURE list)
- Biology
- Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer
- CCC talks for website
- cri
- CRUK CI Lecture Theatre
- CRUK CI Seminars
- Graduate-Seminars
- Liam
- Life Sciences
- Life Sciences
- ME Seminar
- my_list
- other talks
- PMRFPS's
- se393's list
- sfm36
Note: Ex-directory lists are not shown.
![[Talks.cam]](/static/images/talkslogosmall.gif)

Shelley Berger, Epigenetics Institute, Departments of Cell and Developmental Biology, Genetics, Biology, University of Pennsylvania
Thursday 23 February 2017, 16:00-17:00